Light Chain Deposition Disease Diagnosed with Laser Micro-dissection, Liquid Chromatography, and Tandem Mass Spectrometry of Nodular Glomerular Lesions

Tomomichi Kasagi¹, Hironobu Nobata¹, Keisuke Suzuki¹, Naoto Miura¹, Shogo Banno¹, Akiyoshi Takami², Taro Yamashita³, Yukio Ando³ and Hirokazu Imai¹

Abstract

A 42-year-old man developed nephrotic syndrome and rapidly progressive renal failure. Kidney biopsy demonstrated nodular glomerulosclerosis, negative Congo red staining, and no deposition of light or heavy chains. Laser micro-dissection and liquid chromatography with tandem mass spectrometry of nodular lesions revealed the presence of a kappa chain constant region and kappa III variable region, which signified light chain deposition disease. Dexamethasone and thalidomide were effective in decreasing the serum levels of free kappa light chain from 147.0 to 38.0 mg/L, eliminating proteinuria, and halting the worsening of the kidney dysfunction, with serum creatinine levels stable around 4.0 mg/dL for 3 years.

Key words: nodular glomerulosclerosis, light chain deposition disease, microfibril, mass spectrometry

(Intern Med 56: 61-66, 2017)
(DOI: 10.2169/internalmedicine.56.7275)

Introduction

Light chain deposition disease (LCDD) has an incidence of approximately 0.33-0.5% in kidney biopsy specimens (1-3) and is characterized by the deposition of monoclonal light chains in systemic tissues and negative Congo red staining. The diagnosis of LCDD can be easily made with kidney biopsy, as the kidney is usually the affected organ, with manifestations such as proteinuria and decreased kidney function. The characteristic morphological findings of LCDD are nodular glomerulosclerosis and nonfibrillar electron-dense deposits on the glomerular or tubular basement membrane seen with electron microscopy.

We herein present a case of nodular glomerulosclerosis with nephrotic syndrome and rapidly progressive renal failure, which was initially compatible with idiopathic nodular glomerulosclerosis (ING). The final diagnosis of LCDD (kappa chain constant region and kappa III variable region) was made with laser micro-dissection and liquid chromatography with tandem mass spectrometry (LC-MS/MS) of nodular glomerular lesions. We also discuss the treatment for LCDD.

Case Report

A 42-year-old Japanese man was admitted to Aichi Medical University Hospital because of nephrotic syndrome and progressive renal failure. Six months prior to admission, he visited a local hospital for evaluation of bilateral lower extremity edema. He was diagnosed with nephrotic syndrome and progressive renal failure based on data such as a urinary protein level of 3.94 g/g·Cr, serum albumin level of 2.8 g/dL, and serum creatinine level of 2.36 mg/dL. Kidney biopsy at the previous hospital demonstrated nodular glomerulosclerosis in all 29 glomeruli examined (Fig. 1A and B). Deposition was also found in the walls of the small arterioles, but not in the tubular basement membrane or interstitial area. Electron microscopy showed randomly arranged fibrillar structures with a width of 7-13 nm in the subendo-

¹Division of Nephrology and Rheumatology, Aichi Medical University School of Medicine, Japan, ²Division of Hematology, Department of Internal Medicine, Aichi Medical University School of Medicine, Japan and ³Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Japan

Received for publication February 15, 2016; Accepted for publication May 27, 2016
Correspondence to Dr. Tomomichi Kasagi, kasagitiomochi.284@mail.aichi-med-u.ac.jp
The light microscopy findings of the kidney biopsy specimen. (A) Nodular glomerulosclerosis was observed in the glomeruli, PAS ×400. (B) Massive deposition and a nodular pattern in glomeruli, PAS ×200. (C) Negative Congo red staining, Congo red ×50. (D) Negative green birefringence under polarized light with Congo red staining, Congo red ×50.

Figure 2. The electron microscopy findings. Randomly arranged fibrillar structures with a width of 7-13 nm were observed in the subendothelial and mesangial areas. Bar, 200 nm.

The patient was referred to our hospital. He does not smoke, and his medical history and family history were deemed non-contributory.

On admission, his height was 173 cm, body weight 61.0 kg, body temperature 36.8°C, blood pressure 128/68 mmHg, pulse 68 beats/min, and SpO2 98% on room air. A physical examination revealed bilateral lower extremity edema. No macroGLOSSIA, lymphadenopathy, or eruptions were observed. The laboratory studies indicated 2+ proteinuria (1.49 g/day), no occult hematuria, a white blood cell count of 7,900, a red blood cell count of 415×10⁴/μL, hemoglobin of 13.3 g/L, hematocrit of 40.9%, a platelet count of 18.8×10⁴/μL, albumin level of 3.6 g/dL, blood urea nitrogen level of 29.4 mg/dL, serum creatinine level of 4.43 mg/dL, and total cholesterol level of 196 mg/dL. His Na level was 146 mEq/L, K level was 4.3 mEq/L, Cl level was 108 mEq/L, AST level was 235 IU/L, CK level was 52 IU/L, and CRP level was 0.10 mg/dL. His IgG, IgA, and IgM antibody levels were 437 mg/dL, 43 mg/dL, and 99 mg/dL, respectively. His complement C3 level was 77.8 mg/dL (normal range, 60-120 mg/dL), C4 level was 19.2 mg/dL (normal range, 14-40 mg/dL), and CH50 level was 35.5 U/mL (normal range, 30-40 U/mL). The findings for rheumatoid factor, anti-nuclear antibody, hepatitis B antigen, hepatitis C
Figure 3. Immunofluorescence and immunohistochemical studies demonstrated no significant deposition of kappa and lambda light chains. (A) The non-specific findings in the nodular lesions, kappa chain immunofluorescence study, ×200. (B) Small spots were observed in the subendothelial spaces. There were non-specific findings in the nodular lesions in the lambda chain immunofluorescence study, ×200. (C) Negative findings in the nodular lesions, kappa chain immunohistochemical study, ×200. (D) Negative findings in the nodular lesions, lambda chain immunohistochemical study, ×200.

virus antibody, and other autoantibodies were all negative. Immuno-electrophoresis and immunofixation of serum and urine showed no M-proteins. Free kappa and lambda light chain levels were 147.0 and 15.0 mg/L, respectively. His NT-proBNP level was 771 pg/mL (normal range, below 125 pg/mL), and his P-III-P level was 0.84 U/mL (normal range, 0.3-0.8 U/mL). These data suggested partial remission of nephrotic syndrome with oral prednisolone therapy.

Electrocardiography demonstrated low voltage in the limb leads, and transthoracic echocardiography showed a thickened left ventricle wall and interventricular septum (12 mm). Bone marrow aspiration revealed 1.8% plasma cells, and immunostaining and flow cytometry of marrow cells demonstrated no kappa or lambda deflection. Biopsy of adipose tissue from the abdominal wall and random biopsies of lower and upper gastrointestinal tract mucous membranes revealed no immunoglobulin or amyloid deposition. We re-examined the kidney biopsy specimens to clarify the deposition of amyloid and light chains. Congo red staining was negative at our institute and Kumamoto University. Immunofluorescence and immunohistochemical studies demonstrated no significant deposition of immunoglobulin heavy or light chains (Fig. 3) or fibronectin. These findings were consistent with idiopathic glomerulosclerosis.

Laser micro-dissection and LC-MS/MS of the nodular glomerular lesions revealed substantial deposition of the kappa chain constant region and kappa chain III variable region (Fig. 4). However, the level of amyloid P component was very low as a background score. We made a diagnosis of LCDD. He did not have monoclonal proteins in the serum or urine by immunoelectrophoresis and immunofixation, only a predominant free kappa chain in the serum.

After admission, we changed his prednisolone therapy to dexamethasone (Dex) therapy (40 mg/day for 4 days each month), based on the guidelines for multiple myeloma (4), even though prednisolone had been somewhat effective, as evidenced by the gradual decreases in the urinary protein levels. Six months after initiating Dex therapy, his serum levels of free kappa light chain decreased from 147 to 63.7 mg/L, and the kappa/lambda ratio was 2.61. At 12 months after admission, we added 50 mg/day of oral thalidomide (Thal). Thal-Dex therapy was effective in this patient; the serum levels of free kappa light chain decreased to 38 mg/L, his proteinuria resolved (less than 0.3 g/day), and there was no progressive decline in his kidney function, with serum creatinine levels stable around 4.0 mg/dL for 3 years.
Discussion

Nodular glomerulosclerosis has been reported to be the most characteristic finding in patients with diabetic nephropathy or amyloid nephropathy. It is also found in patients with dysproteinemias such as LCDD and heavy chain deposition disease (HCDD). Recently, nodular glomerulosclerosis was also observed in fibronectin nephropathy and collagenofibrotic glomerulopathy. In addition to these diseases, in 1989, Herzenberg et al. proposed ING as a new disease entity characterized by the absence of diabetes mellitus, amyloidosis, and immunoglobulin deposition without a known etiology (5). They emphasized the influence of hypertension and smoking. In 2002, Markowirz et al. reported that 23 out

(Fig. 5). Follow-up echocardiography revealed a stable cardiac function, and his NT-proBNP levels had decreased to 557 pg/mL at 18 months after admission.

Discussion

Nodular glomerulosclerosis has been reported to be the most characteristic finding in patients with diabetic nephropathy or amyloid nephropathy. It is also found in patients with dysproteinemias such as LCDD and heavy chain deposition disease (HCDD). Recently, nodular glomerulosclerosis was also observed in fibronectin nephropathy and collagenofibrotic glomerulopathy. In addition to these diseases, in 1989, Herzenberg et al. proposed ING as a new disease entity characterized by the absence of diabetes mellitus, amyloidosis, and immunoglobulin deposition without a known etiology (5). They emphasized the influence of hypertension and smoking. In 2002, Markowirz et al. reported that 23 out
of 5073 kidney biopsy specimens were compatible with ING. There was male predominance (18 males and 5 females), and 96% and 70% of patients had hypertension and nephrotic syndrome, respectively. Serum creatinine levels greater than 1.2 mg/dL were observed in 83% of patients, and 56% of patients developed progressive renal failure over an observation period of 14 months (6). They suggested hypertension and smoking as causes of ING. Nasr and D’Agati also emphasized the role of smoking in ING in 2007 (7).

The present case was initially compatible with ING, because there was no significant deposition of immunoglobulin heavy or light chains, negative Congo red staining of nodular glomerular lesions, normal glucose tolerance, no increase in the number of plasma cells in the bone marrow, no M-proteins in the serum and urine, and a more significant increase in the levels of free light chain kappa than of lambda. Laser micro-dissection of the nodular lesions and LC-MS/MS revealed that the major deposited proteins consisted of the kappa chain constant region and kappa chain type III variable region, which signifies LCDD (kappa type). We found a similar case in the literature (8), where LC-MS/MS of a nodular pulmonary lesion revealed kappa light chains, signifying LCDD (kappa) of the lung, with negative Congo red staining and an immunofluorescence study.

LC-MS/MS is an extremely useful tool for diagnosing unknown deposition diseases. In amyloidosis, it is known that immunofluorescence and immunohistochemical studies are sometimes negative because the degeneration or decomposition of antigen epitopes occurs during and after amyloid fibril formation. It is reported that mass spectrometry-based proteomics were able to determine the type of amyloidosis in 95% of cases compared with 69% of cases by immunohistochemistry (9). Similarly, 6% of LCDD are reported to show negative findings on immunofluorescence studies (10). Our case revealed the potential value in performing a proteomics analysis, especially when no other approaches reveal the contents of deposition.

The incidence of LCDD has been found to range from 0.33% to 0.5% in kidney biopsy specimens (1-3), which is less than the 1% for amyloidosis (11, 12). Nodular glomerulosclerosis associated with LCDD is emphasized with light microscopy; however, only 60% of LCDD patients have nodular lesions. The remaining patients have mesangial expansion or basement membrane depositions (13). Under electron microscopy, dense granular deposits are present in the mesangial area and subendothelial space without fibrillar structures; however, 8% of patients with LCDD have 8- to 20-nm fibrillar structures present (14). This patient also had random fibrillar structures on electron microscopy. Interestingly, in this case, LC-MS/MS revealed the presence of a serum amyloid P (SAP) component weaker than that of the kappa chain constant region and kappa chain type III variable region and serum albumin. SAP is a normal circulating plasma protein suspected of playing some role in amyloid fibril formation (15). However, the relationship between SAP and LCDD is unclear, and further investigation is necessary. Kappa light chains are predominant in 80-90% of LCDD patients (16, 17), compared to the predominance of lambda chains in amyloidosis. Kappa IV and I light chain variable region LCDD has been reported as the most common type of LCDD (18-20). Kappa III variable region has been also reported; truncated kappa III variable region caused LCDD in one patient (21). When subjected to in vitro fibrillar-formation experiments, the kappa III variable type of Bence-Jones protein adopts a fibrillar conformation only at an acidic pH and remains aggregated but not fibrillar at physiological pH (22).

The natural course of LCDD is associated with a very poor prognosis, with 97% of patients having serum creatinine levels greater than 1.2 mg/dL (average, 3.9 mg/dL) at the time of LCDD diagnosis, 39% of patients developing end-stage renal failure over 34 months of observation, and 32% of patients dead at a mean observation duration of 18 months (13). The combination of multiple myeloma (RR 2.75), and extra-renal deposition (RR 2.24) are prognostic risk factors for life (23).

Regarding therapy for LCDD, drugs used to treat multiple myeloma are recommended by the guidelines for multiple myeloma when LCDD patients are complicated with multiple myeloma. In patients with LCDD not accompanied by multiple myeloma, hematopoietic stem cell transplantation and chemotherapy with thalidomide, dexamethasone, bortezomib, lenalidamide, and alkylating drugs are recommended (17). A case report was published of a patient with LCDD that responded to chemotherapy, with no nodular glomerular lesions seven years after chemotherapy (24). It is very important to use adequate drugs for reducing the levels of free light chain.

Regarding the formation of nodular glomerular lesions, dysproteins such as light chain or heavy chain stimulate mesangial cells to produce mesangial matrix components such as collagen and tenascin via NF-kB in LCDD. The proteasome inhibitor bortezomib, which directly interferes with and inhibits NF-kB, is a promising drug for reducing the formation of glomerular nodular lesions (25). We have to monitor serum levels of free light chains and consider chemotherapy to maintain stable levels.

The authors state that they have no Conflict of Interest (COI).

References
1. Gallo GR, Feiner HD, Katz LA, et al. Nodular glomerulopathy associated with nonamyloidotic kappa light chain deposits and excess immunoglobulin light chain synthesis. Am J Pathol 99: 621-644, 1980.
2. Pozzi C, D’Amico M, Fogazzi GB, et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis 42: 1154-1163, 2003.
3. Masai R, Waku H, Togashi M, et al. Clinicopathological features and prognosis in immunoglobulin light and heavy chain deposition disease. Clin Nephrol 71: 9-20, 2009.
4. Engelhardt M, Terpos E, Kleber M, et al. European Myeloma Net-
work recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99: 232-242, 2014.

5. Herzenberg AM, Holden JK, Singh S, Magil AB. Idiopathic nodular glomerulosclerosis. Am J Kidney Dis 34: 560-564, 1999.

6. Markowitz GS, Lin J, Valeri AM, Avila C, Nasr SH, D’Agati VD. Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. Hum Pathol 33: 826-835, 2002.

7. Nasr SH, D’Agati VD. Nodular glomerulosclerosis in the nondiabetic smoker. J Am Soc Nephrol 18: 2032-2036, 2007.

8. Arrossi AV, Merzianu M, Farver C, et al. Nodular pulmonary light chain deposition disease: an entity associated with Sjögren syndrome or marginal zone lymphoma. J Clin Pathol 69: 490-496, 2016.

9. Said SM, Reynolds C, Jimenez RE, et al. Amyloidosis of the breast: predominantly AL type and over half have concurrent breast hematologic disorders. Mod Pathol 26: 232-238, 2013.

10. Golden N, Barlogie B, Liapis H. Morphologic heterogeneity of renal light-chain deposition disease. Ultrastruct Pathol 32: 17-24, 2008.

11. Yokoyama H, Sugiyama H, Sato H, et al. Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol 16: 903-920, 2012.

12. Mesquita M, Fosso C, Bakoto Sol E, et al. Renal biopsy findings in Belgium: a retrospective single center analysis. Acta Clin Belg 66: 104-109, 2011.

13. Nasr SH, Valeri AM, Cornell LD, et al. Renal monoclonal immunoglobulin deposition disease: a report of 64 patients from a single institution. Clin J Am Soc Nephrol 7: 231-239, 2012.

14. Joh K. Pathology of glomerular deposition diseases. Pathol Int 57: 551-565, 2007.

15. Richards DB, Cookson LM, Berges AC, et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. N Engl J Med 373: 1106-1114, 2015.

16. Said S, J Cooper C, Nwosu A, E Bilbao J, T Hernandez G. Hypertension, renal failure, and edema in a 38-year-old man: light chain deposition disease; a case report and review of the literature. J Nephropathol 3: 63-68, 2014.

17. Jimenez-Zepeda VH. Light chain deposition disease: novel biological insights and treatment advances. Int J Lab Hematol 34: 347-355, 2012.

18. Cogné M, Pread’homme JL, Bawens M, Touchard G, Aucouturier P. Structure of a monoclonal kappa chain of the V kappa IV subgroup in the kidney and plasma cells in light chain deposition disease. J Clin Invest 87: 2186-2190, 1991.

19. Rocca A, Khamlichi AA, Aucouturier P, et al. Primary structure of a variable region of the V κI subgroup (ISE) in light chain deposition disease. Clin Exp Immunol 91: 506-509, 1993.

20. Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P. Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 12: 1558-1565, 2001.

21. Decourt C, Cogné M, Rocca A. Structural peculiarities of a truncated V κ III immunoglobulin light chain in myeloma with light chain deposition disease. Clin Exp Immunol 106: 835-843, 1999.

22. Paueksakon P, Revelo MP, Horn RG, Shappell S, Fogo AB. Monoclonal gammopathy: significance and possible causality in renal disease. Am J Kidney Dis 42: 87-95, 2003.

23. Komatsuda A, Wakuji H, Ohtani H, et al. Disappearance of nodular mesangial lesions in a patient with light chain nephropathy after long-term chemotherapy. Am J Kidney Dis 35: E9, 2000.

24. Rezzani A, Vidal R, Kaplan B, et al. pH-dependent fibrillogensis of a VκIII Bence Jones protein. Br J Haematol 107: 835-843, 1999.

25. Decourt C, Cogné M, Rocca A. Structural peculiarities of a truncated VκIII immunoglobulin light chain in myeloma with light chain deposition disease. Clin Exp Immunol 106: 357-361, 1996.

26. Ronco PM, Alyanakian MA, Mougenot B, Aucouturier P. Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level. J Am Soc Nephrol 12: 1558-1565, 2001.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).